This session will review the Transfusion Transmissible Infections Monitoring System (TTIMS) program scope and activities. TTIMS is funded by the US Food and Drug Administration, National Heart, Lung, and Blood Institute, and the Office of the Assistance Secretary for Health in the Department of Health and Human Services. Four large blood collection agencies currently participate in TTIMS. This educational program will provide the audience with contemporary information and results covering how the TTIMS program monitors blood safety in the US and how this program is geared to evaluate the impact donor policy changes may have on the safety of the blood supply. Knowledge of TTIMS and the tools which are in place are relevant for AABB Annual Meeting attendees as the US moves to individual donor assessment approaches to blood donor selection. Specifically, we will describe our methods and findings on the prevalence, incidence, and residual risks of transfusion-transmissible infections (TTI) in donations, HIV incidence in first-time donors including novel approaches to residual risk estimation, and behavioral risk factors and biomarker monitoring of risk of TTIs in US donations.
Describe the development of a multi-center monitoring system with consensus definitions for TTI’s, and how resulting TTI data are used to monitor prevalence, incidence, and residual risks over time.
Explain how additional testing of viral load for HIV, HCV, and HBV and limiting antigen avidity testing to classify HIV infections as recently acquired or long-term are used to inform calculation of incidence in first time donors and biomarker approaches to monitor changes in incidence over time.
Outline the additional tools the TTIMS program uses to evaluate blood supply safety in the US, including donor risk factor interviews, findings from molecular surveillance of infections identified in donations, and assessment of antiretroviral use in blood donors.